In Brief This Week: Agendia; Gen-Probe, Neogen; Synthetic Biology Industry Association; Biodesign Institute, Intel | GenomeWeb

NEW YORK (GenomeWeb News) – Agendia this week said that Palmetto GBA, California's Part B Medicare administrator, has established coding guidelines for the firm's MammaPrint test. It said patients in the US can now submit claims for the MammaPrint test directly to Palmetto GBA in California where the test results are analyzed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.